Rewire Weekly is one science backed protocol every Tuesday, drawn from the latest longevity and neuroscience research. I am a practitioner and researcher. The goal is not wellness content. It is clinical evidence translated into something you can actually use.

Eighteen adults took the equivalent of 30 grams of whole Lion's Mane mushroom and were tested for cognitive performance 90 minutes later. The result: no statistically significant improvement in global cognitive function. No mood improvement. The only measurable effect was a modest improvement in fine motor performance on a pegboard task.

This is not evidence that Lion's Mane does not work. It is evidence that the community has been running the wrong experiment. A structural neuroplasticity intervention cannot be evaluated on an acute timeline. The mechanism does not operate on that timescale. Understanding why requires understanding what Lion's Mane is actually doing at the gene expression level, how long those effects take to manifest as measurable structural change, and what the five randomized controlled trials that ran the correct timeline actually found.

Lion's Mane (Hericium erinaceus) contains two classes of bioactive compounds found in no other species: hericenones, concentrated in the fruiting body, and erinacines, concentrated in the mycelium. Both classes cross the blood brain barrier, a property that distinguishes them from most dietary polyphenols, which act primarily at the gut wall or in peripheral tissue.

Inside the central nervous system, these compounds stimulate gene expression for nerve growth factor synthesis. NGF is not a neurotransmitter. It is a trophic signal: a protein that binds to the TrkA receptor on neurons and activates downstream MAPK and PI3K signaling cascades. These cascades regulate neuronal survival, axonal and dendritic branching, and in the hippocampus, the maintenance of ongoing neurogenesis. The mechanism is confirmed in vitro and in animal models. The five human RCTs confirm the clinical cognitive outcomes but have not yet confirmed the specific intracellular pathway in vivo. That distinction matters for how we interpret what we know and how confidently we can extrapolate.

This is why the acute dosing data looks flat. You cannot stimulate NGF gene expression once and detect the structural downstream output 90 minutes later. Dendritic arborization, axonal maintenance, and hippocampal neuron density are structural changes. They accumulate over weeks of sustained upregulation, not hours after a single dose. Evaluating Lion's Mane at 90 minutes is like testing the effect of strength training 90 minutes after the first workout. The experiment is measuring the wrong window.

Erinacine A, the most studied mycelium compound, also activates Nrf2, an endogenous antioxidant transcription factor that upregulates the body's own oxidative defense systems. This means Lion's Mane is operating on two parallel tracks simultaneously: NGF driven structural neuroplasticity via TrkA activation, and Nrf2 mediated neuroprotection against oxidative damage. The cognitive outcomes in the clinical trials are likely a product of both running concurrently.

Five randomized controlled trials have been published on Lion's Mane with cognitive outcomes in humans. This is the highest quality evidence currently available for this compound. A 2025 systematic review by Menon and colleagues (Frontiers in Nutrition) analyzed all five alongside 15 preclinical studies and found a combined weighted mean increase of 1.17 points on the MMSE in intervention groups. MMSE is a 30 point cognitive screening scale. A 1.17 point shift from a dietary supplement, measured in studies not designed to correct for ceiling effects in cognitively healthy adults, is a meaningful signal from a literature this size.

The strongest individual trial for cognitive outcomes enrolled 33 subjects in a double blind RCT over 8 weeks using erinacine A enriched mycelium extract. Černelič Bizjak and colleagues (2024, Journal of Functional Foods) found statistically significant improvement in cognitive performance on nonverbal speed tasks, alongside measurable increases in gut microbiota diversity. SCFA producing bacteria increased in the intervention group and their abundance was positively correlated with neuropeptide Y levels. NPY is an anti inflammatory neuropeptide involved in stress regulation and hippocampal plasticity. The gut to brain connection here is not speculative. It is a quantified chain: mushroom compounds produce a microbiota composition shift, which increases SCFA production, which elevates NPY, which supports hippocampal plasticity.

A separate 12 week double blind placebo controlled parallel group trial by Saitsu and colleagues (2019, Biomedical Research) using fruiting body extract found MMSE improvement and prevented cognitive deterioration in the intervention arm across the full study period. No adverse events were reported. Together, these trials establish that 8 to 12 weeks of consistent daily dosing is where the signal lives. Neither trial found meaningful acute effects.

The Menon 2025 systematic review also found consistent reduction in anxiety, depression, binge eating, and sleep disorder symptoms across intervention groups. These outcomes do not appear in most Lion's Mane marketing. They represent a reproducible secondary signal with direct relevance for anyone managing cognitive load alongside chronic stress.

What this evidence does not support: acute cognitive enhancement. The Surendran 2025 trial (Frontiers in Nutrition) gave 18 adults 3 grams of a validated 10:1 fruiting body extract and tested them 90 minutes later. No significant effect on global cognitive function or mood. This is the most practically useful finding in this literature because it explains why a large fraction of users report that Lion's Mane does nothing. They are evaluating a chronic structural intervention on an acute timeline. The minimum evaluation window is 8 weeks. The stronger evidence window is 12 weeks. Stopping at week 4 because nothing is perceptible is not a failed experiment. It is an incomplete one.

The community conversation around Lion's Mane treats it as a functional cognitive enhancer to evaluate over days. Both Andrew Huberman and Rhonda Patrick have characterized the NGF mechanism and the animal data accurately. Neither has emphasized the acute versus chronic distinction to the degree the Surendran 2025 data now demands. That gap is the most common driver of user dropout before the intervention has had any chance to work.

The product quality problem is separate and equally real. Most consumer Lion's Mane products use mycelium cultivated on grain substrates: oats and rice. These products are predominantly grain starch. The actual mushroom material and its active compound concentration is low. Beta glucan content is the proxy quality marker: a credible extract states this number explicitly. Fruiting body with stated beta glucan content, or erinacine enriched mycelium with specified erinacine content, are the forms that match the clinical data. If a label does not confirm 100% fruiting body sourcing and does not state beta glucan content, the probability that you are consuming meaningful quantities of hericenones or erinacines is low.

Chong and colleagues (2019, International Journal of Molecular Sciences) reviewed the neurotrophic mechanisms linking Hericium erinaceus to antidepressant potential and concluded that the NGF promoting effects of hericenones and erinacines represent a legitimate pathway to mood regulation. This pathway is mechanistically distinct from the serotonin and dopamine targets of pharmaceutical antidepressants, which is worth understanding if you are considering this compound alongside or instead of standard mood support approaches.

The mechanism runs as follows: sustained NGF upregulation maintains hippocampal neuron density, which preserves the hippocampus's capacity for ongoing neurogenesis, which reduces the structural deficit associated with chronic depression and anxiety symptom burden. This is the neuroplasticity theory of antidepressant action applied to a dietary compound. The idea is that structural hippocampal changes, not acute monoamine modulation, are the substrate of sustained mood improvement. The human trial data does not yet confirm this at the cellular level; the clinical mood outcomes are reproduced across the systematic review, but the specific pathway from compound to mood in humans remains to be confirmed in vivo.

The gut microbiota data from Černelič Bizjak 2024 adds a second vector to the same outcome. Lion's Mane increased the abundance of SCFA producing bacteria, which generate butyrate and propionate. These short chain fatty acids reduce systemic and neuroinflammation through multiple pathways, including microglial polarization toward anti inflammatory phenotypes. Reduced microglial activation creates a more permissive environment for hippocampal neurogenesis. The chain runs from gut flora composition shift to butyrate and propionate production to reduced microglial activation to anti inflammatory neurological environment to hippocampal plasticity. Each step in that chain is quantified in the 2024 trial.

If your primary interest is cognitive performance, the MMSE data from the five trial systematic review is the anchor. If your interest extends to anxiety management, stress resilience, or mood regulation, the antidepressant and gut to brain data provides a second mechanistic rationale for the same intervention at the same dose.

Lion's Mane fruiting body extract (dual extracted, beta glucan standardized, 100% fruiting body, no grain filler)

The quality markers to require on the label: 100% fruiting body confirmation, stated beta glucan content as a specific percentage or milligram amount, and dual extraction confirming both water soluble and alcohol soluble fractions. The clinical dose is 1,800mg daily across two servings. Avoid products listing mycelium on grain as the substrate without specified erinacine content. That product is predominantly grain starch, not mushroom material, and is unlikely to deliver the hericenone or erinacine concentrations the trials used.

I currently run this at 900mg with breakfast and 900mg with dinner, both of which include dietary fat. I have reviewed the available options against the clinical evidence and the most reliably standardized forms are available through my Fullscript dispensary at a discount below retail. Lion's Mane is included alongside the full cognitive and longevity stack I use and recommend.

If this issue was useful, forward it to one colleague who tracks their health seriously. That is the most direct way to help this newsletter grow.

Have a question about the research or a specific stack you want me to look at? Reply to this email. I read every response.